These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36692636)

  • 21. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay.
    Förster S; Grimmer T; Miederer I; Henriksen G; Yousefi BH; Graner P; Wester HJ; Förstl H; Kurz A; Dickerson BC; Bartenstein P; Drzezga A
    Biol Psychiatry; 2012 May; 71(9):792-7. PubMed ID: 21679929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
    Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
    Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population.
    Huang KL; Lin KJ; Hsiao IT; Kuo HC; Hsu WC; Chuang WL; Kung MP; Wey SP; Hsieh CJ; Wai YY; Yen TC; Huang CC
    PLoS One; 2013; 8(3):e58974. PubMed ID: 23516589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Weng R; Ren S; Su J; Ni W; Yang C; Gao X; Xiao W; Zhang X; Jiang H; Guan Y; Huang Q; Gu Y
    Brain Imaging Behav; 2023 Apr; 17(2):185-199. PubMed ID: 36637715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of dementia risk in aging adults using both FDG-PET and FDDNP-PET imaging.
    Ercoli LM; Small GW; Siddarth P; Kepe V; Huang SC; Miller KJ; Lavretsky H; Bookheimer SY; Barrio JR; Silverman DH
    Int J Geriatr Psychiatry; 2012 Oct; 27(10):1017-27. PubMed ID: 22383132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings.
    Delorme C; Paccoud O; Kas A; Hesters A; Bombois S; Shambrook P; Boullet A; Doukhi D; Le Guennec L; Godefroy N; Maatoug R; Fossati P; Millet B; Navarro V; Bruneteau G; Demeret S; Pourcher V;
    Eur J Neurol; 2020 Dec; 27(12):2651-2657. PubMed ID: 32881133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment.
    Wu L; Rowley J; Mohades S; Leuzy A; Dauar MT; Shin M; Fonov V; Jia J; Gauthier S; Rosa-Neto P;
    PLoS One; 2012; 7(10):e47905. PubMed ID: 23112868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease.
    Frings L; Hellwig S; Spehl TS; Bormann T; Buchert R; Vach W; Minkova L; Heimbach B; Klöppel S; Meyer PT
    Brain; 2015 Oct; 138(Pt 10):3089-99. PubMed ID: 26280595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.
    Blazhenets G; Frings L; Sörensen A; Meyer PT;
    J Nucl Med; 2021 Jun; 62(6):855-860. PubMed ID: 33097630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study.
    Kas A; Soret M; Pyatigoskaya N; Habert MO; Hesters A; Le Guennec L; Paccoud O; Bombois S; Delorme C;
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2543-2557. PubMed ID: 33452633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
    Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
    Wang Y; Lou F; Li Y; Liu F; Wang Y; Cai L; Gordon ML; Zhang Y; Zhang N
    Curr Alzheimer Res; 2021; 18(6):523-532. PubMed ID: 34598664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regional glucose metabolism due to the presence of cerebral amyloidopathy in older adults with depression and mild cognitive impairment.
    Youn H; Lee ES; Lee S; Suh S; Jeong HG; Eo JS
    J Affect Disord; 2018 Oct; 239():30-36. PubMed ID: 29991443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain Glucose Metabolism in Cerebral Amyloid Angiopathy: An FDG-PET Study.
    Bergeret S; Queneau M; Rodallec M; Landeau B; Chetelat G; Hong YT; Dumurgier J; Hugon J; Paquet C; Farid K; Baron JC
    Stroke; 2021 Apr; 52(4):1478-1482. PubMed ID: 33611942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.
    Lehmann M; Ghosh PM; Madison C; Karydas A; Coppola G; O'Neil JP; Huang Y; Miller BL; Jagust WJ; Rabinovici GD
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):266-73. PubMed ID: 23965289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurology; 2007 Feb; 68(7):501-8. PubMed ID: 17065593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.